Salary Range:CHF169,400.00 - CHF314,600.00 BandLevel 7 Job Description Summary#LI-Hybrid Location: Basel, Switzerland We’re a team of dedicated international lawyers united by our purpose to reimagine medicine for patients in need and our drive to achieve together.
About the Role The Medical Science Liaison (MSL) / Medical Advisor serves as DKSHs subject matter expert on key indications within the neurology or ophthalmology portfolio, developing and driving medical affairs strategy and activities in Singapore.
At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are,
BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our
Location of role Zug, Switzerland Department Medical Affairs - EU Key Responsibilities The Autoimmune Research team has, in recent years, advanced novel therapeutic approaches to modulate and suppress the immune system in a targeted manner within
Immunocore in Zug, Switzerland is seeking a Senior Manager, Field Medical Affairs to serve as the primary field-based medical liaison with KOLs, HCPs and investigators. You will deliver medical education, provide scientific data on Immunocore products, and support
Position Summary The Senior Director, Head of Medical Evidence reports into the Vice President, Head of Disease Areas and coordinates with Medical Affairs and cross-functional stakeholders to lead the Integrated Evidence Generation Plans (IEGP) for all
BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our
BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our
BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our
BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our
Who We AreThe Product Development Safety (PDS) organization delivers patient-centric scientific safety solutions that build trust and create value for society, leading to smarter safety design and decision-making activities throughout the drug lifecycle. PDS sustains Pharmacovigilance
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our
Job Purpose The VP, Medical Affairs, Rare Diseases BU will provide strategic medical leadership and oversight to support the continued growth of the Rare Diseases (RRD) portfolio. S/he will champion patient centricity as key driver of
BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)